Entera Bio Improving Its EB612 Add-on Therapy, Publishes Earlier Study
Entera Bio is developing a better formulation of EB612, its add-on therapy for maintaining normal blood calcium levels in people with hypoparathyroidism, and expects to launch a clinical trial next year. The biotechnology company shared its plans while announcing the publication of an earlier Phase 2a study of…